Abstract
Introduction
Cardiovascular disease is the largest single cause of death among women in the US. The American Heart Association guidelines recommend aspirin use in women ≥65 years of age if blood pressure is controlled and the benefits of cardiovascular risk reduction likely outweigh the risk of bleeding. The objective of this study is to determine the prevalence of aspirin use in elderly women and factors associated with use.
Methods
This retrospective study evaluated aspirin use in women aged ≥65 years based on cardiovascular and gastrointestinal bleeding risk using a medication therapy management database within a large mid-Atlantic managed care organization. Logistic regression was used to analyze patient-related variables associated with aspirin use. Variables included clinical coronary heart disease (CHD), number of CHD risk factors, diabetes diagnosis, number of chronic medications and presence of contraindications to aspirin.
Results
Aspirin use was reported in 50% of patients: 68.0% in the secondary prevention group and 46.3% in the primary prevention group. The percentage of patients using aspirin or with relative aspirin contraindications increased to 84% for the secondary prevention group and 65.9% for the primary prevention group. Patients with clinical CHD and those with diabetes and without clinical CHD were 5.88 (P=0.008) and 7.54 (P=0.012) times more likely to utilize aspirin, respectively, than patients with only one CHD risk factor of age. Patients with relative contraindications to aspirin were less likely to use aspirin (P<0.001).
Conclusion
The high use of aspirin in patients at higher CHD risk supports national recommendations. Clinical practitioners need to carefully assess the value of aspirin in patients at low CHD risk and those 80 years of age and beyond where evidence of benefit should be weighed against risk.
Similar content being viewed by others
References
American Heart Association. Heart Disease and Stroke Statistics: 2010 Update At-A-Glance. Dallas, Texas: American Heart Association; 2010. c2010, American Heart Association. Available at: www.americanheart.org/downloadable/heart/1265665152970DS-3241%20HeartStrokeUpdate_2010.pdf. Accessed June 1, 2010.
Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86.
US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;150:396–404.
Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevent ion of cardiovascular disease in women. N Engl J Med. 2005;352:1293–1304.
Chan AT, Manson JE, Feskanich D, Stampfer MJ, Colditz GA, Fuchs CS. Long-term aspirin use and mortality in women. Arch Intern Med. 2007;167:562–572.
Mosca L, Banka, CL, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation. 2007;115:1451–1501.
Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47:533–543.
Pignone M, Anderson GK, Binns K, Tilson HH, Weisman SM. Aspirin use among adults aged 40 and older in the United States: results of a national survey. Am J Prev Med. 2007;32:403–407.
Berger JS, Brown DL, Burke GL, et al. Aspirin use, dose, and clinical outcomes in postmenopausal women with stable cardiovascular disease. Circ Cardiovasc Qual Outcomes. 2009;2:78–87.
Cho L, Hoogwerf B, Huang J, Brennan DM, Hazen SL. Gender differences in utilization of effective cardiovascular secondary prevention: a Cleveland clinic prevention database study. J Womens Health (Larchmt). 2008;17:515–521.
Ajani UA, Ford ES, Greenland KJ, Giles WH, Mokdad AH. Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System. Am J Prev Med. 2006;30:74–77.
Stafford RS, Monti V, Ma J. Underutilization of aspirin persists in US ambulatory care for the secondary and primary prevention of cardiovascular disease. PLoS Med. 2005;2:e353. Epub 2005 Nov 15.
American Diabetes Association. Standards of medical care in diabetes — 2007. Diabetes Care. 2007;30(suppl. 1):S4–41.
American Diabetes Association. Standards of medical care in diabetes — 2009. Diabetes Care. 2009;32(suppl. 1):S13–S61.
Laine L. Review article: gastrointestinal bleeding with low-dose aspirin — what’s the risk? Aliment Pharmacol Ther. 2006;24:897–908.
Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849–1860.
Lip GYH, Felmeden DC. Antiplatelet agents and anticoagulants for hypertension. Cochrane Database Syst Rev. 2008;(4):CD003186.
Redberg RF, Benjamin EJ, Bittner V, et al. ACCF/AHA 2009 Performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures (Writing committee to develop performance measures for primary prevention of cardiovascular disease): developed in collaboration with the American Academy of Family Physicians; American Association of cardiovascular and Pulmonary Rehabilitation; and Preventive Cardiovascular Nurses Association; endorsed by the American College of Preventive Medicine, American college of Sports Medicine, and Society for Women’s health Research. Circulation 2009;120:1296–1336.
Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;150:405–410.
De Berardis G, Sacco M, Strippoli GF, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ. 2009;339:b4531.
Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295:306–313.
Persell SD, Zei C, Cameron KA, Zielinski M, Lloyd-Jones DM. Potential use of 10-year and lifetime coronary risk information for preventive cardiology prescribing decision: a primary care physician survey. Arch Intern Med. 2010;170:470–477.
Romero SC, Dela Rosa KM, Linz PE. Aspirin for primary prevention of coronary heart disease: using the Framingham Risk Score to improve utilization in a primary care clinic. South Med J. 2008;101:725–729.
Rodondi N, Vittinghoff E, Cornuz J, et al. Aspirin use for the primary prevention of coronary heart disease in older adults. Am J Med. 2005;118:1288
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lee, H.Y., Tong, Y.P., Xing, S. et al. Aspirin use in elderly women receiving medication therapy management services. Adv Therapy 27, 613–622 (2010). https://doi.org/10.1007/s12325-010-0046-1
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12325-010-0046-1